Redhill Biopharma Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K report covers the month of May 2026 for Redhill Biopharma Ltd., a foreign private issuer headquartered in Tel Aviv, Israel. The filing primarily addresses a corporate action regarding the Company's capital raising activities under an existing At The Market (ATM) Offering Agreement.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a corporate transaction rather than a financial results statement.
Material Changes
- ATM Offering Increase: On May 7, 2026, the Company filed a prospectus supplement to increase the maximum aggregate offering amount of American Depositary Shares (ADS) available under its ATM Offering Agreement with H.C. Wainwright & Co., LLC.
- Share Structure: Each ADS represents ten thousand (10,000) ordinary shares with a par value of NIS 0.01 per share.
- Agreement Date: The underlying ATM agreement was originally entered into on February 3, 2025.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or specific risk factors beyond the standard incorporation of legal opinions. The document includes legal opinions from Goldfarb Gross Seligman & Co. and Haynes and Boone, LLP, regarding the validity of the shares to be issued.
Investor Verification Checklist
- Verify the specific dollar amount of the increase to the ATM offering cap in the referenced prospectus supplement.
- Review the terms of the original ATM agreement dated February 3, 2025, to understand the scope of the new authorization.
- Confirm the current cash position and burn rate in the most recent quarterly or annual report (Form 20-F or 6-K) to assess the necessity of this capital raise.
- Check for any subsequent filings regarding the actual issuance of shares under this expanded ATM program.